Literature DB >> 7322682

Vasopressin and pneumothorax in the neonate.

P Stern, F T LaRochelle, G A Little.   

Abstract

The release of vasopressin (AVP) was assessed by measuring urinary excretion of the hormone in ten neonates who had an acute and symptomatic pneumothorax in the first three days after birth. AVP excretion rose significantly (paired t analysis) after the pneumothorax occurred. When apparent re-expansion of the lungs occurred after treatment, excretion of AVP returned to prepneumothorax levels within eight to 16 hours. If the pneumothorax persisted or worsened. AVP excretion remained elevated. Urine osmolality rose significantly (paired t analysis) after pneumothorax, presumably in response to the increased AVP levels. Two of the ten infants had hyponatremia in the period studied, while in a state of sodium balance. It was concluded that AVP release is increased after a pneumothorax occurs. This increase is apparently not due to osmoregulatory requirements. Fluid intake in these infants may need adjustment to prevent an inappropriate positive water balance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7322682

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  4 in total

1.  Air leaks and vasopressin release.

Authors:  N McIntosh; P Prakash; A Smith
Journal:  Arch Dis Child       Date:  1990-11       Impact factor: 3.791

2.  Central transmural venous pressure and plasma arginine vasopressin during negative pressure breathing in man.

Authors:  P Norsk; F Bonde-Petersen; J Warberg
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1986

3.  Hyponatraemia in the first week of life in preterm infants. Part I. Arginine vasopressin secretion.

Authors:  L Rees; C G Brook; J C Shaw; M L Forsling
Journal:  Arch Dis Child       Date:  1984-05       Impact factor: 3.791

4.  Serial measurement of plasma arginine vasopressin in the newborn.

Authors:  N McIntosh; A Smith
Journal:  Arch Dis Child       Date:  1985-11       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.